Clinical trial · Interventional
Glizigen-Viudid-External Anogenital Warts in Children and Adolescents
Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to assess the efficacy of Glizigen and Viusid administration in the treatment of external anogenital warts in children and adolescents. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons to be recruited and randomized for the study is 76. Variables to be assessed will be: time to disappearance of lesions, reduction of the number of lesions and change in the aspect of lesions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| External Anogenital Warts | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Glizigen + Viusid | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Glizigen + Viusid
- interventionNames
- Dietary Supplement: Glizigen + Viusid
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- Time to lesion regression
- timeFrame
- 12 weeks
- description
- Excellent: Lesion regression before 2 weeks of treatment Good: Lesion regression between 2-5 weeks of treatment Poor: Lesion regression between 5-8 weeks of treatment Bad: No lesion regression after 8 weeks of treatment.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * No previous treatment for anogenital warts * Negative serology for HB and HIV. * Signed informed consent. Exclusion Criteria: * Pregnancy * Treatment with steroids, immune-suppressors, immune-modulators or local or systemic antiviral drugs. * Hypersensitivity to Glizigen or Viusid:
References
Publications (0)
Data not yet available